Moderna Says CHMP Recommends Marketing Authorization For MRESVIA RSV Vaccine In EU
(RTTNews) - Moderna, Inc. (MRNA) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of marketing authorization in the European Union for mRESVIA (mRNA-1345) to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
Following the CHMP's positive opinion, the European Commission will adopt a decision on the authorization of mRESVIA, an mRNA respiratory syncytial virus (RSV) vaccine.
RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia. The CHMP positive opinion for mRESVIA is based on positive data from the Phase 3 clinical trial ConquerRSV, a global study conducted in approximately 37,000 adults ages 60 years or older in 22 countries.
In May 2024, the U.S. Food and Drug Administration (FDA) approved mRESVIA (mRNA-1345) to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection.
FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants
Moderna Reports Positive Phase 3 Data For Flu And COVID Combination Vaccine
Moderna Stock Up 6% As Q4 Results Top Estimates
CDC Recommends Updated Pfizer, Moderna COVID-19 Vaccine
Moderna, Immatics Ink Strategic Multi-Platform Collaboration To Develop Oncology Therapeutics
Moderna Says Clinical Trial Data Shows Updated COVID Vaccine Very Effective Against BA.2.86 Variant
FDA Authorizes Changes To Simplify Use Of Moderna, Pfizer Bivalent COVID-19 Vaccines
